Spyre Therapeutics (SYRE) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$486.2 million.
- Spyre Therapeutics' Enterprise Value fell 1737.48% to -$486.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$486.2 million, marking a year-over-year decrease of 1737.48%. This contributed to the annual value of -$603.1 million for FY2024, which is 7775.68% down from last year.
- According to the latest figures from Q3 2025, Spyre Therapeutics' Enterprise Value is -$486.2 million, which was down 1737.48% from -$526.6 million recorded in Q2 2025.
- Over the past 5 years, Spyre Therapeutics' Enterprise Value peaked at -$38.5 million during Q1 2023, and registered a low of -$603.1 million during Q4 2024.
- For the 5-year period, Spyre Therapeutics' Enterprise Value averaged around -$266.7 million, with its median value being -$203.6 million (2023).
- In the last 5 years, Spyre Therapeutics' Enterprise Value soared by 4731.96% in 2022 and then crashed by 115952.75% in 2024.
- Over the past 5 years, Spyre Therapeutics' Enterprise Value (Quarter) stood at -$93.1 million in 2021, then soared by 40.18% to -$55.7 million in 2022, then crashed by 508.99% to -$339.3 million in 2023, then plummeted by 77.76% to -$603.1 million in 2024, then rose by 19.38% to -$486.2 million in 2025.
- Its Enterprise Value was -$486.2 million in Q3 2025, compared to -$526.6 million in Q2 2025 and -$564.8 million in Q1 2025.